We have full service cell culture capabilities to demonstrate whether or not a cell has the capacity of performing certain functions. Currently we have assays to evaluate Natural Killer Cell Cytoxicity Assay and a Basophil Activation Test (BAT). Please inquire to start the scientific discussion.
NK cytotoxicity assay – We have developed and offer a flow cytometry based NK cytotoxicity assay to evaluate human and non-human primate NK cell effector function. K562 target cells are labeled with PKH67 (a fluorescent green dye that labels the cell membrane) to discriminate target cells from effector cells. Then, effector cells (PBMCs) are incubated with the PKH67 labeled K562 target cells at different Effector to Target (E:T) cell ratios from 100:1, 50:1 and 25:1. After co-culture, the cell mixtures are stained with 7-AAD (7-Aminoactinomycin D) which is a fluorescent chemical compound with a strong affinity for DNA used to detect dead cells (Figure 1).
Figure 1. Schematic representation of the interaction of PKH67 labeled K562 target cells with NK effector cells in PBMC.
The percentages of 7AAD positive (dead) K562 target cells are determined by flow cytometry at each Effector to Target (E:T) ratio tested. A comparison of NK cell cytotoxicity in human and Non-Human Primate (NHP) in the presence or absence of IL-2, a cytokine which can enhance NK cell effector function. In addition to evaluating NK cytolytic activity, each donor can be immunophenotyped for their NK cell number.
Figure 2. Ratio of Effector: Target cells (E:T) vs the % Cytotoxicity of human and NHP NK cells. Human and NHP NK cytolytic activity is highest at the 100:1 E:T ratio, with a dose-dependent decline as the E:T ratio decreases. IL-2 enhances both human and NHP NK cytotoxicity.
Basophil Activation Test (BAT) – FCSL offers the Basophil Activation Test for research and clinical applications. BAT is currently used for the evaluation of various allergic conditions, such as environmental allergens, food allergens and drug allergies including the assessment of clinical response to allergen-specific immunotherapy and other immunomodulatory treatments. The BAT offers an easy in vitro assay to test patient sensitivity to various substances prior to the initiation of clinical trials.
To test the reliability and efficacy of the BAT at FCSL, we performed a qualification study using a commercially available basophil activation kit (Flow CAST®, Buhlmann). Blood samples were incubated under 3 separate conditions: unstimulated, stimulated with fMLP (N-Formylmethionine-leucyl-phenylalanine, a positive control for basophil degranulation) and stimulated with dust mite allergen. Each sample was stained for CCR3 (a basophil identification marker) along with CD203c and CD63 (basophil activation markers) during incubation. After incubation, red blood cells were lysed, and the samples washed and analyzed using a flow cytometry with results shown in Figure 3.
Figure 3. Top Panel (A) – Basophil surface marker changes with allergen encounter include up-regulation of both CD63 (LAMP3) and CD203c (ENPP3). CD63 is a found on membranes of intracellular vesicles and is only exposed on the cell surface with activation and degranulation. Bottom Panel (B) – Histogram overlay comparing the expression of CD63 on the surface of unactivated basophils (orange) to samples that have been activated by exposure to antigen (purple). Bottom Panel (C) – The evaluation of dust mite antigen for two subjects, Patient 1, has clear dust mite allergy while Patient 2, is negative for dust mite allergy.
For more information on how we can help you to evaluate NK function or basophil activation in non-clinical and clinical studies or evaluate your drug for its effect on cellular function please inquire to start the discussion.